Panzyga IVIG
Phase 2Small molecule
Panzyga IVIG is one of 23 small molecule programs targeting Neuropathy. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Neuropathy
#DrugCompanyPhaseTrials
1Elavil
AstraZenecaApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Accupril
PfizerApproved
Pamelor
SSpecgx
Approved
Mexitil
Boehringer IngelheimApproved
Epsom Salt
FFresenius Kabi USA, LLC
Approved
Immunoglobulin
SanofiPhase 3
Rituxan
RochePhase 2
Calquence
AstraZenecaPhase 2
Calciferol
Jazz PharmaceuticalsPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Panzyga IVIG. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEndeavor Health